Abstract
The ends of all eukaryotic chromosomes are protected by specialized nucleoprotein complexes called telomeres. When functional and intact, telomeres prevent end-to-end fusions, inappropriate DNA repair mechanisms, and DNA degradation. Often referred to as biological clocks, telomeres are repeatedly shortened during each replication cycle due to incomplete replication by DNA polymerases. When critically short, telomeres become dysfunctional or uncapped, losing their higher-order structures and ability to protect the chromosome, an event referred to as the “end-replication problem.” This telomere instability prompts cells to enter a growth arrest state and trigger DNA damage responses (DDRs) such as cellular senescence and apoptosis. In addition, due the guanine rich properties of telomeric DNA, they can form intramolecular G-quadruplexes, four-stranded DNA structures that are stabilized by the stacking of guanine residues in a planar arrangement. However, the functional roles of telomeric G-quadruplexes are not understood. In cancer cells, telomere length is maintained by telomerase, a ribonucleoprotein enzyme complex with reverse transcriptase activity, which adds TTAGGG repeats to the 3’ telomere end. Telomerase is comprised of two sub-units: hTERT, the catalytic component of telomerase, and hTR, an RNA template complementary to the 3’ overhang. While telomerase is generally inactive in normal somatic cells, early studies demonstrated that telomerase is overexpressed in more than 85% of cancers, and its activity is believed to be a requirement for malignant cells to achieve immortality. Hence, telomerase and the telomere components which regulate it have been regarded as near-universal cancer targets and have become an active focus of cancer researchers. Currently, telomere-based targets are being tested as potential diagnostic and prognostic markers of cancers.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Artandi SE, DePinho RA. Telomeres and telomerase in cancer. Carcinogenesis. 2010;31:9–18.
Catarino R, Araujo A, Coelho A, et al. Prognostic significance of telomerase polymorphism in non-small cell lung cancer. Clin Cancer Res. 2010;16:3706–12.
de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 2005;19:2100–10.
Geron Corporation. A study of active immunotherapy with GRNVAC1 in patients with acute Myelogenous Leukemia (AML) 2013 [2013 Nov 29]. Available from: http://clinicaltrials.gov/ct2/show/NCT00510133?term=grnvac1&rank=1)
Hiyama K, editor. Telomeres and telomerase in cancer. Springer; 2009.
Holysz H, Lipinska N, Paszel-Jaworska A, Rubis B. Telomerase as a useful target in cancer fighting-the breast cancer case. Tumour Biol. 2013;34:1371–80.
Neidle S, Parkinson GN. The structure of telomeric DNA. Curr Opin Struct Biol. 2003;13:275–83.
Poremba C, Heine B, Diallo R, et al. Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. J Pathol. 2002;198:181–9.
Puri N, Girard J. Novel therapeutics targeting telomerase and telomeres. J Cancer Sci Ther. 2013;39(5):444.
Riffell JL, Lord CJ, Ashworth A. Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nat Rev Drug Discov. 2012;11:923–36.
Roth A, Harley CB, Baerlocher GM. Imetelstat (GRN163L) – telomerase-based cancer therapy. Recent Results Cancer Res. 2010;184:221–34.
Ruden M, Puri N. Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev. 2013;39:444–56.
Sampathi S, Chai W. Telomere replication: poised but puzzling. J Cell Mol Med. 2011;15:3–13.
Seimiya H, Muramatsu Y, Ohishi T, Tsuruo T. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. Cancer Cell. 2005;7:25–37.
Shalaby T, Fiaschetti G, Nagasawa K, et al. G-quadruplexes as potential therapeutic targets for embryonal tumors. Molecules. 2013;18:12500–37.
Shay JW, Keith WN. Targeting telomerase for cancer therapeutics. Br J Cancer. 2008;98:677–83.
Simonsson T. G-quadruplex DNA, structures – variations on a theme. Biol Chem. 2001;382:621–8.
van Steensel B, de Lange T. Control of telomere length by the human telomeric protein TRF1. Nature. 1997;385:740–3.
Yang D, Okamoto K. Structural insights into G-quadruplexes: towards new anticancer drugs. Future Med Chem. 2010;2:619–46.
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media New York
About this entry
Cite this entry
Wojdyla, L., Frakes, M., Harrington, K., Stone, A., Puri, N. (2017). Telomerase-Related Proteins. In: Marshall, J. (eds) Cancer Therapeutic Targets. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0717-2_146
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0717-2_146
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-0716-5
Online ISBN: 978-1-4419-0717-2
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences